Table 1 Patients characteristics
Patients characteristics | All patients | Patients with TMJ involvement on MRI | Patients without TMJ involvement on MRI |
|---|---|---|---|
Total no. of patients, n (%) | 76 | 53 (70) | 23 (30) |
Female, n (%) | 42 (55) | 29 (69) | 13 (31) |
Oligoarticular, n (%) | 24 (32) | 17 (32) | 7 (30) |
Enthesitis related arthritis n (%) | 9 (12) | 7 (13) | 2 (9) |
Oligoarticular extended, n (%) | 11(15) | 7 (13) | 4 (17) |
Polyarticular RF neg, n (%) | 25 (33) | 19 (36) | 6 (26) |
Systemic, n (%) | 1 (1) | 1 (2) | 0 (0) |
PsA, n (%) | 2 (3) | 1 (2) | 1 (4) |
Unclassified, n (%) | 4 (5) | 1 (2) | 3 (13) |
Age at diagnosis, median (range), years | 5.5 (1–14.9) | 5.4 (1–19.4) | 6.6 (1.1–14.1) |
Age at examination, median (range), years | 9.7 (1.9–18.6) | 9.6 (1.9–18.6) | 9.8 (4.8–17.8) |
Disease duration, median (range), years | 2.4 (0.0–15.7) | 1.9 (0.0–15.4) | 3.5 (0.1–15.7) |
HLA-B27 positive/tested, n (%) (n = 59) | 6 (10) | 4 (10) | 2 (11) |
ANA positive, n (%) (n = 74) | 47 (64) | 33 (62) | 14 (61) |
Uveitis, n (%) | 11 (15) | 6 (11) | 5 (22) |
Treatment with systemic disease-modifying drugs, n (%) | 31 (41) | 23 (43) | 8 (35) |
Infliximab, n (%) | 4 (5) | 4 (10) | 0 (0) |
Etanercept, n (%) | 1 (1) | 0 (0) | 1 (4) |
Methotrexate, n (%) | 31 (41) | 23 (43) | 8 (35) |